by nms-sync | Feb 1, 2023 | News
NERVIANO, IT and BOSTON, Mass, 01 February 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today...
by nms-sync | Jan 13, 2023 | News
NERVIANO, IT and BOSTON, Mass, January 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the...
by nms-sync | Jan 10, 2023 | News
NEWS
MPS1 Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer
The targeted drug NMS-01940153E, a monopolar spindle 1 (MPS1) kinase inhibitor, has shown signs of clinical activity in a Phase I study of patients with relapsed or...
by nms-sync | Jan 10, 2023 | News
Nerviano, 9 January 2023 NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership...
by nms-sync | Nov 4, 2022 | News
A week from the presentation of Nerviano Medical Sciences S.r.l. (a member of NMS Group) on NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, we’re thrilled to share the official press release from ENA 2022 of...
by nms-sync | Oct 31, 2022 | News
NERVIANO, 31 October 2022 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Salvatore Marengoni Galdy, M.D., has joined the...
Welcome and Check out our new motion picture!
Recent Comments